AstraZeneca
AZN
455 hedge funds and large institutions have $12.7B invested in AstraZeneca in 2017 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 171 increasing their positions, 123 reducing their positions, and 54 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 123
19% more call options, than puts
Call options by funds: $167M | Put options by funds: $140M
3% more capital invested
Capital invested by funds: $12.3B → $12.7B (+$418M)
0.57% more ownership
Funds ownership: 14.25% → 14.82% (+0.57%)
2% less funds holding
Funds holding: 466 → 455 (-11)
11% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 54
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$175M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$139M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$127M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$99.5M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$82.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$208M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$177M |
| 3 |
Jennison Associates
New York
|
-$67.6M |
| 4 |
Goldman Sachs
New York
|
-$37.7M |
| 5 |
Barclays
London,
United Kingdom
|
-$28M |
AZN Hedge Fund Activity: Q3 2017 in Review
455 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2017, worth a combined $12.7B — up 3.4% from $12.3B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of AZN and 48 opened new positions — a net loss of 6 holders — while 123 trimmed existing stakes and 171 added.
The largest buyer was Primecap Management, adding an estimated $175M. The largest seller was Capital International Investors, cutting an estimated $208M.
- 455 institutional investors held AstraZeneca (AZN) as of Q3 2017, down from 466 in Q2 2017.
- Funds reported $12.7B of AstraZeneca stock for Q3 2017, up 3.4% quarter-over-quarter.
- 48 funds opened new AstraZeneca positions in Q3 2017 and 54 closed out, a net change of -6 holders.
- The largest AstraZeneca buyer in Q3 2017 was Primecap Management, an estimated $175M added.
- The largest AstraZeneca seller in Q3 2017 was Capital International Investors, an estimated $208M sold.
Based on aggregated 13F filings for Q3 2017.